|
|
 Previous Article | Table of Contents | Next Article 
Soluble kit receptor in human serum
J Wypych, LG Bennett, MG Schwartz, CL Clogston, HS Lu, VC Broudy, TD Bartley, VP Parker and KE Langley
Amgen, Inc, Amgen Center, Thousand Oaks, CA 91320-1789.
c-kit encodes the transmembrane receptor tyrosine kinase (Kit) for the
recently described ligand stem cell factor (SCF). We have developed an
enzyme-linked immunosorbent assay for measuring soluble human Kit and we
have used the assay to show high levels of soluble Kit in human serum. The
distribution of soluble Kit levels was investigated among 112 normal human
serum donors. The mean serum level (+/- SD) was found to be 324 +/- 105
ng/mL with the values falling between 163 ng/mL and 788 ng/mL. No
correlation between soluble Kit levels and the sexes or ages of the donors
was found. Partial purification using immunoaffinity chromatography allowed
us to characterize the soluble Kit from pooled human serum. Antibodies
generated to a 497-amino acid recombinant human soluble Kit corresponding
to the N-terminal extracellular domain of the receptor recognized the
serum-derived soluble Kit by immunoblotting. We found that the
serum-derived soluble Kit is glycosylated, with mostly N- linked but also
O-linked carbohydrate, and with terminal sialic acid residues. When
compared with the recombinant human soluble Kit, the serum-derived material
was similar both in size and glycosylation pattern. CNBr cleavage of the
isolated serum-derived material followed by amino terminal sequencing
confirmed the presence of five peptides expected for the extracellular
portion of the Kit molecule. The immunoaffinity purified serum-derived
soluble Kit inhibited binding of [125I]SCF to membrane-bound receptor in an
in vitro assay. These results indicate that soluble Kit could modulate the
activity and functions of SCF in vivo.
Volume 85,
Issue 1,
pp. 66-73,
01/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Kent, M. Copley, C. Benz, B. Dykstra, M. Bowie, and C. Eaves
Regulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway
Clin. Cancer Res.,
April 1, 2008;
14(7):
1926 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sakao, L. Taraseviciene-Stewart, C. D. Cool, Y. Tada, Y. Kasahara, K. Kurosu, N. Tanabe, Y. Takiguchi, K. Tatsumi, T. Kuriyama, et al.
VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells
FASEB J,
November 1, 2007;
21(13):
3640 - 3652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.J. Hutt, E.A. McLaughlin, and M.K. Holland
Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis
Mol. Hum. Reprod.,
February 1, 2006;
12(2):
61 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
Blood,
April 15, 2004;
103(8):
2929 - 2935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Cruz, B. T. Frank, S. T. Edwards, P. F. Dazin, J. J. Peschon, and K. C. Fang
Tumor Necrosis Factor-{alpha}-converting Enzyme Controls Surface Expression of c-Kit and Survival of Embryonic Stem Cell-derived Mast Cells
J. Biol. Chem.,
February 13, 2004;
279(7):
5612 - 5620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al.
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clin. Cancer Res.,
January 15, 2004;
10(2):
751 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Akin, L. B. Schwartz, T. Kitoh, H. Obayashi, A. S. Worobec, L. M. Scott, and D. D. Metcalfe
Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
Blood,
August 15, 2000;
96(4):
1267 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Lyman and S. E. W. Jacobsen
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
Blood,
February 15, 1998;
91(4):
1101 - 1134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Broudy
Stem Cell Factor and Hematopoiesis
Blood,
August 15, 1997;
90(4):
1345 - 1364.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-R. Hsu, G.-M. Wu, E. A. Mendiaz, R. Syed, J. Wypych, R. Toso, M. B. Mann, T. C. Boone, L. O. Narhi, H. S. Lu, et al.
The Majority of Stem Cell Factor Exists as Monomer under Physiological Conditions. IMPLICATIONS FOR DIMERIZATION MEDIATING BIOLOGICAL ACTIVITY
J. Biol. Chem.,
March 7, 1997;
272(10):
6406 - 6415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Philo, J. Wen, J. Wypych, M. G. Schwartz, E. A. Mendiaz, and K. E. Langley
Human Stem Cell Factor Dimer Forms a Complex with Two Molecules of the Extracellular Domain of Its Receptor, Kit
J. Biol. Chem.,
March 22, 1996;
271(12):
6895 - 6902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
